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Available online 16 October 2013Abstract Bone marrow stromal cells (BMSCs, also known as bone marrow-derived mesenchymal stem cells) can differentiate
into multiple lineages including osteogenic and adipogenic cells. Wnt signalling has been implicated in controlling BMSC fate,
but the mechanisms are unclear and apparently conflicting data exist. Here we show that a novel glycogen synthase kinase 3β
inhibitor, AR28, is a potent activator of canonical Wnt signalling using in vitro β-catenin translocation studies and TCF-reporter
assays. In vivo, AR28 induced characteristic axis duplication and secondary regions of chordin expression in Xenopus laevis
embryos.
Using human BMSCs grown in adipogenic medium, we confirmed that AR28-mediated Wnt signalling caused a significant
(p b 0.05) dose-dependent reduction of adipogenic markers. In osteogenic media, including dexamethasone, AR28 caused
significant (p b 0.05) decreases in alkaline phosphatase (ALP) activity compared to vehicle controls, indicative of a
reduced osteogenic response. However, when excluding dexamethasone from the osteogenic media, increases in both ALP
and mineralisation were identified following AR28 treatment, which was blocked by mitomycin C. Pre-treatment of BMSCs
with AR28 for 7 days before osteogenic induction also increased ALP activity and mineralisation. Furthermore, BMP2-induced
osteogenic differentiation was strongly enhanced by AR28 addition within 3 days, but without concomitant changes in cell
number, therefore revealing BMP-dependent and independent mechanisms for Wnt-induced osteogenesis.
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Bone marrow stromal cells (BMSCs), a subset of which have
stem cell-like properties (and are sometimes referred to as
bone marrow-derived mesenchymal stem cells) are capable
of self renewal and differentiation into multiple lineages,
including osteoblasts, adipocytes and chondrocytes (Pittenger
et al., 1999). BMSCs are derived, as the name suggests, from
the bone marrow, however stromal cells with similar cell
surface characteristics can be isolated frommany other stromal
tissues, including adipose tissue and periosteum (da Silvaer B.V. All rights reserved.
416 D.A. Cook et al.Meirelles et al., 2006). These stromal cells isolated from
different tissues however cannot be considered the same and
require further in-depth comparisons (Bianco et al., 2008).
BMSCs are also suitable for ex vivo expansion, which alongside
their ability to differentiate intomultiple cell typesmakes them
an attractive candidate in regenerative medicine. However,
the use of BMSCs for these purposes is limited by an incomplete
understanding of the regulation of BMSC proliferation and
differentiation. One regulatory mechanism attracting consider-
able attention in BMSC control is the canonical Wnt signalling
pathway. Wnt signalling is an important pathway both in
embryonic development and adult tissue homeostasis, regulat-
ing many processes including development, cell proliferation
and cell fate (Ling et al., 2009). Wnt signalling acts through the
canonical pathway involving β-catenin, as well as β-catenin
independent non-canonical pathways. The canonical Wnt path-
way mediates its effects by binding to their receptors frizzled
(Fzd) and co-receptors, low-density lipoprotein receptor relat-
ed protein (LRP) 5 and 6. This causes activation of intracellular
Dishevelled which in turn inhibits a protein destruction com-
plex. This results in the stabilisation and nuclear translocation
of β-catenin, inducing gene transcription via the LEF/TCF
family of transcription factors. In the absence of Wnt
signalling, the destruction complex is not inhibited, and
phosphorylates β-catenin, through glycogen synthase ki-
nase 3β (GSK3β), leading to its ubiquitination and pro-
teosomal degradation.
The involvement of canonical Wnt signalling in bone
homeostasis was first identified in osteoporosis pseudoglioma
syndrome patients, who had a loss of function mutation in LRP5
resulting in reduced bone density (Gong et al., 2001) whilst gain
of function mutations in LRP5 caused increases in bone density
(Boyden et al., 2002). These findings stimulated interest in the
therapeutic use of canonicalWntmanipulation to regulate bone
mass. Initial mouse models with enhanced canonical Wnt
signalling, through LRP5 overexpression (Babij et al., 2003),
sFRP1 knock down (Bodine et al., 2004) and LiCl (a crude GSK3
inhibitor) administration (Clement-Lacroix et al., 2005), were
also promising, showing increased bone mass. However the
manner in which canonical Wnts generate this anabolic effect is
less clear. One proposal is through the increased differentiation
of mesenchymal cells into osteoblasts. The differentiation of
mouse mesenchymal precursors is enhanced by the activation
of canonical Wnt (Kulkarni et al., 2006; Bennett et al., 2005),
supporting this hypothesis. However, the effect of canonical
Wnt signalling on the differentiation of human BMSCs is less
straightforward. For example, Boland et al. (2004) reported
that Wnt3a conditioned media caused inhibition of osteogenic
differentiation, yet appeared to increase proliferation of
human BMSCs. The current reasoning for these discrepancies is
that the degree of activation and the cell type which is
stimulated is very important. Eijken et al. (2008) demonstrated
that activation of canonicalWnt during glucocorticoid (GC, such
as dexamethasone)-induced differentiation of human foetal
osteoblastic cells caused reduced alkaline phosphatase (ALP)
activity and mineralisation, but increased the ALP activity
of their pre-osteoblast population. Similarly, Krause et al.
(2010) demonstrated an increase in the early dexamethasone-
independent differentiation of human BMSCs stimulated with
canonical Wnt signalling. These findings suggest that canonical
Wnt can stimulate early osteoblast differentiation in a GC-
independent manner, but inhibits dexamethasone-induceddifferentiation. Interestingly, the stimulation of early osteog-
enic differentiation is not sufficient to induce mineralisation in
these studies, and dexamethasone addition was required for
final maturation. However, these studies do not attempt to
explain the mechanism by which canonical Wnt signalling
causes the increased early osteogenic differentiation. Another
method that has been used to induce osteogenesis is the
administration of bone morphogenetic proteins (BMPs)
(Knippenberg et al., 2006; Lee et al., 2000). While BMPs
are also capable of generating a comparable osteogenic
response to dexamethasone, it is thought that they act
through different mechanisms. There is also evidence for a
role of canonical Wnt signalling in BMP-induced differentiation
of mouse mesenchymal lines (Rawadi et al., 2003), suggesting
the requirement of a functional canonical Wnt signalling
cascade. GCs are generally considered necessary for in vitro
bone nodule formation and mineralisation of BMSCs, and can
induce the expression of many osteogenic genes (Beresford et
al., 1994). However, there is also evidence for GC-induced
osteoporosis after prolonged administration in humans. This
effect is currently attributed to the stimulation of BMSCs toward
the adipogenic lineage, and the suppression of osteoblast
proliferation and increased apoptosis of mature osteoblasts
(Canalis et al., 2007). Canonical Wnt signalling has been
identified as a key player in GC-induced osteoporosis, through
the identification of reduced Wnt upon GC administration
(Wang et al., 2008) and the rescue of GC-induced osteoporosis
by GSK3β inhibition by 6-bromoindirubin-3′-oxime (BIO) (Wang
et al., 2009).
Current activators of Wnt such as recombinant Wnt ligands,
LiCl and BIO have limitations as investigative tools which may
contribute to the discrepancies in the findings relating to
canonicalWnt and BMSC differentiation. Firstly, the availability
of bioactive recombinant Wnt ligands is limited. While this is
continuously improving with the generation of new ligands,
there is still the added complexity of ligand-specific effects, an
area which is still relatively poorly understood. While LiCl
and BIO circumvent this problem by acting on GSK3β,
downstream of the ligand/receptor binding, they are not
ideal, with off target effects and toxicity (Davies et al.,
2000; Meijer et al., 2003; Liu et al., 2011). Here we present
a novel GSK3α/β inhibitor, AR28, and demonstrate its
ability to selectively activate canonical Wnt signalling in a
dose- and time-dependent manner in vitro and in vivo using
a developmental Xenopus model. Using AR28 as a tool to
activate Wnt, we confirmed the effects of canonical Wnt on
human BMSC adipogenesis and identified BMP-dependent
and -independent Wnt-mediated control of BMSC osteo-
genic differentiation.
Materials and methods
Cell culture
The mouse cell line, C3H10T1/2 was cultured in Dulbecco's
Modified Eagle Medium (DMEM) (GIBCO, # S41966-052) with
10% foetal bovine serum (FBS) and 100 U/ml Penicillin/
100 μg/ml Streptomycin (P/S). Human BMSCs, following
informed consent, were extracted from the bone marrow
of femoral heads (as in Etheridge et al., 2004) and knee
surgery patients by migration from fractured bone samples
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cultured in DMEM with 15% FBS and P/S. For confirmation of
adipogenic assays, human adipose derived stromal cells (ADSCs)
(Invitrogen) were used (see section 2.6) and cultured in
MesenPRO RS (Invitrogen). All cells were incubated at 37 °C
in 5% CO2/95% air humidified atmosphere. All assays were
performed in basal medium (DMEM, 10% FBS, 1% P/S) with the
addition of either osteogenic or adipogenic supplements (given
below) when stated.
TCF-luciferase (TOPFlash) reporter assays
C3H10T1/2 cells were seeded at 3.2 × 103 cells/cm2 in a
white 96 well plate (without antibiotics) and allowed to
attach overnight. The cells were then transfected, using
Lipofectamine and Plus Reagent, with 0.03 μg/well TOPFlash
DNA and 0.003 μg/well pCMVRenilla. 24 h after transfection,
AR28 treatment was initiated. After a determined time period
the samples were analysed using the Dual Glo Luciferase assay
system (Promega Cat# E2920), using a 96 well plate lumino-
meter. For analysis, firefly luciferase was normalised to Renilla
to reduce the effect of differences in transfection efficiencies
between wells.
Axis duplication in Xenopus laevis
Xenopus laevis embryos were obtained as described pre-
viously (Godsave et al., 1988). Embryos were cultured until
the four cell stage when a single ventral blastomere was
microinjected into ventral marginal zone with AR28 or DMSO
control. Embryos were cultured until Nieuwkoop and Faber
stage 40 (Nieuwkoop & Faber, 1994) and fixed in 4%
formaldehyde in PBS. Whole mount in-situ hybridisation
was carried out using a modified version of the Harland
protocol (Tindall et al., 2005).
Differentiation studies
BMSCs were seeded at 2 × 104 cells/cm2 and allowed to
attach overnight. For osteogenic differentiation the medi-
um was then replaced with osteogenic medium (Basal
medium plus 50 μg/ml L-ascorbic acid-2-phosphate, 5 mM
β-glycerophosphate, 10 nM Dexamethasone, unless stated
otherwise). BMP2 (NIBSC, #93/574) treatments were per-
formed at 100 ng/ml. For adipogenic differentiation the
medium was replaced with adipogenic medium (Basal
medium plus 1 μM Dexamethasone, 500 μM 3-isobutyl-1-
methylxanthine (IBMX), 1 μg/ml Insulin, 100 μM indomethacin).
Medium was changed every 3–4 days.
Oil Red O staining
Lipid droplets were visualised using Oil Red O staining. Cells
were washed with PBS followed by fixation with 4% para-
formaldehyde for 10 min. The cells were then washed once in
dH2O and incubated in 60% isopropanol for 5 min. The
isopropanol was removed and followed by an incubation in
Oil Red O staining solution (0.3% Oil Red O in 60% isopropanol)
for 10 min, washed once in 60% isopropanol and 3 times with
dH2O. The samples were stored in 20% glycerol in PBS andimaged using bright field microscopy. For quantification, Oil
Red O was extracted using 100% isopropanol (50 μl/well) for
10 min and absorbances measured (490 nm).
FABP5/BODIPY staining
ADSCs were fixed in 4% paraformaldehyde for 15 min,
followed by washing in PBS. The cells were then blocked in
PBS supplemented with 1.1% BSA (SIGMA) and 0.2% Triton-
X-100 for 30 min at room temperature. Anti-FABP5 (R&D
systems) was added overnight at 4 °C in blocking buffer. The
cells were washed in blocking buffer before addition of Alexa
Fluor 647 donkey anti-goat IgG (Invitrogen) and Hoechst
33342 in blocking buffer for 1 h at room temperature. The
cells were washed three times in PBS followed by BODIPY
staining in PBS for 40 min at room temperature. Cells were
then washed and stored in PBS at 4 °C. Images were taken
using an automated ImageXpress 5000A (Molecular Devices)
using a 10× S Fluor Objective and analysed using Definiens
automated image analysis.
Alkaline phosphatase enzyme histochemistry, von
Kossa Staining
BMSCs were washed with PBS, followed by treatment with
ALP reagent mix (0.2 mg/ml naphtol AS-MX in 1% N,
N-dimethylformamide diluted in 0.1 M Tris (base) pH 9.2,
plus 1 mg/ml Fast Red TR). Cells were then washed in PBS
before fixation with 4% paraformaldehyde for 5 min,
followed by single washes in PBS and dH2O. Mineralisation
was visualised using the von Kossa technique with the
addition of 1% silver nitrate solution and left on a light box
for 30 min. Cells were subsequently washed with dH2O,
treated with 2.5% sodium thiosulphate for 5 min and washed
again with dH2O, before storage in 20% glycerol in PBS and
imaged using bright field microscopy.
Alizarin Red staining
Calcification of osteogenic monolayers was also visualised
using Alizarin Red S (AR-S) Staining. Cells were washed with
PBS followed by fixationwith 4% PFA for 15 min. The cells were
then washed 3 times in PBS before staining with 40 mM Alzarin
Red S solution (pH4.2) for 20 min at room temperature. Excess
stain was removed by PBS and H2O washes. Plates were
allowed to dry prior to imaging. The AR-S stain was then
solubilised by incubation at 37 °C in 10% cetylpyridinium
chloride (dissolved in 10 mM sodium phosphate, pH 7.0) for
2 h. Sample absorbance was measured at 570 nm and
compared to a standard curve.
p-Nitrophenyl Phosphate (pNPP) alkaline
phosphatase assay
Differentiated cells grown in a 96 well plate were washed
with 0.2 M Carbonate Buffer (0.2 M Na2CO3, 0.2 M NaHCO3,
pH 10.2), and lysed in 150 μl lysis buffer (0.1% Triton X-100 in
carbonate Buffer). Cells were then freeze thawed (−80 °C/
37 °C) 3 times and stored at −80 °C. 50 μl aliquots were
removed from each sample well and the alkaline phosphatase
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Sigma-Aldrich) as a substrate (0.3 mg/mL pNPP, 3.3 mM
magnesium chloride in 0.2 M carbonate buffer) against p-
nitrophenyl (Sigma-Aldrich) standards. Sample absorbance
was measured at 405 nm. To measure the DNA content, 50 μl
aliquots were taken from each sample well the wells were
treated with Quant-iT picogreen reagent (Invitrogen Cat#
P7581) and the fluorescence measured (458 nm excitation and
538 nm emission). ALP activity was then calculated as ng
pNPP/min/μg.
MTT assay
BMSCs were seeded at 2 × 104 cells/cm2 in 96 well plates,
and allowed to attach overnight. Treatments were then
applied in replicates of 6, and replaced every 3–4 days. The
cells were cultured for 4 or 7 days before the medium was
removed and replaced with 100 μl basal medium plus 25 μl
5 mg/ml MTT (in PBS). Medium and MTT was also added to
wells without cells as background controls. The samples
were cultured at 37 °C, 5% CO2 for 2 h to allow the cells to
convert the soluble MTT into insoluble formazan. The
media/MTT was then removed and formazan solubilised by
30 min incubation in acidic isopropanol (0.04 M HCl in 100%
isopropanol). Once in solution the absorbance was measured
at 570 nm using a plate reader. The mean blank value was
subtracted from the sample absorbance readings, and
presented as bar charts of the mean absorbance ± standard
deviation for each treatment. For inhibition of BMSC
proliferation, 10 μg/ml mitomycin C (Sigma Aldrich) was
used. Cells were incubated for 2 h before removal of the
mitomycin C and washed twice with PBS.
RNA extraction and cDNA synthesis
RNA was extracted from cell layers using Trizol (Life
technologies) according to the Life technologies protocol. RNA
was treated using the DNA-free Kit (Invitrogen, CA) and
quantified spectrometrically. Starting from 0.5 μg RNA 20 μl
of cDNA was synthesised using 1 μl Oligo dt primers (Invitrogen,
CA) and 1 μl SuperScript II (Invitrogen, CA) in the presence of
dNTPs. Samples were diluted to 50 μl in nuclease free H2O.
Real-time reverse transcriptase PCR
cDNA samples were diluted 1:5 for the genes of interest, and
1:100 for RPS27A, before combining into the reaction mix in
triplicate in a 96 well plate format, and assayed using the ABI
Prism 7000. 5 μl of cDNA was used (for total 25 μl reaction
volume) were added to each reaction mix, including 12.5 μl
SYBR Green Power (Invitrogen, CA) and 0.8 μM forward and
reverse primers. Genes of interests were normalised to the
housekeeping gene, and plotted as fold change in expression
levels. Primer sequences were as follows; RPS27A Sense:
TGGATGAGAATGGCAAAATTAGTC, antisense: CACCCCAGC
ACCACATTCA (GenBank # BC066293). Runx2 Sense: AGTG
ATTTAGGGCGCATTCCT, antisense: GGAGGGCCGTGGGTT
CT (GenBank # NM_001024630). ALP sense: GGGAACG
AGGTCACCTCCAT, antisense: TGGTCACAATGCCCACAGAT
(GenBank # NM_000478). Sox9 sense: TTCCGCGACGTGGA
CAT, antisense: TCAAACTCGTTGACATCGAAGGT (GenBank# BC007951). Aggrecan sense: AGTATCATCAGTCCCAGAA
TCTAGCA, antisense: AATGCAGAGGTGGTTTCACTC (GenBank
# NM_001135). Coll2a1 sense: TTGCCTATCTGGACGAAGCA,
antisense: CGTCATTGGAGCCCTGGAT (GenBank # BC007252).
Statistical analysis
All experiments were analysed using Mann–Whitney U tests
or Kruskal–Wallis 1-way ANOVA tests for multiple comparisons.
All results are expressed as the mean ± standard deviation.
Significance p values are less than 0.05. * p b 0.05, ** p b 0.01,
*** p b 0.001.
Results
AR28 Stimulates canonical Wnt signalling in vitro
and in vivo
To analyse the in vitro capability of AR28 to induce
a canonical Wnt response, the stabilisation of β-catenin
was studied. Using human BMSCs and a mouse cell line,
C3H10T1/2, AR28 caused the nuclear translocation of β-
catenin, visualised by β-catenin immunocytochemistry,
and generated a dose-dependent increase in stable de-
phosphorylated β-catenin when analysed by SDS-PAGE and
western blotting (Fig. S1).
In order to analyse the ability of AR28 to selectively
activate a functional Wnt response, an in vivo Xenopus
model system was used. Injection of 4.6 nl of AR28 at
concentrations of 100–400 μM generated a dose-dependent
axis duplication event in X. laevis embryos, visible as
Y-shaped dorsal axis (Fig. 1A) and second heads (Fig. 1B),
with 58% of the treated embryos showing some level of axis
duplication with 200 and 400 μM AR28. Furthermore, the
severity of the axis duplication increased with increasing
AR28 concentrations, identified by a higher occurrence of
duplicated eyes (Table S1). Upon sectioning, these embryos
clearly showed secondary neural tube formation, further
confirming the axis duplication event (Fig. S2).
Axis duplication of Xenopus embryos is a well documented
result of increased canonical Wnt signalling (Sokol et al., 1991),
however similar effects can also be generated by manipulating
other signalling pathways such as BMPs that act after organiser
region formation (Suzuki et al., 1994). Chordin is a marker for
the Spemann organiser (Sasai et al., 1994), offering a more
specific readout of canonical Wnt activation. Using in-situ
hybridization we found that the injection of 400 μM AR28
resulted in clear second regions of chordin expression in the
ventral side of the embryo in 95% of the injected samples
(Fig. 1C). No secondary regions were detected in control
embryos. These data conclusively demonstrate that AR28
induces a specific functional canonical Wnt response in vivo
and in vitro.
TCF/LEF1 reporter assay
In order to analyse the trancriptional responses generated by
AR28, we used a TOPFlash luciferase reporter, which uses
the TCF/LEF1 binding site to report Wnt signalling activity.
TOPFlash analysis was carried out in C3H10T1/2 cells,
Figure 1 AR28 generates a functional canonical Wnt signalling in vivo and vitro. Four cell stage embryos were injected into the
marginal zone of one ventral blastomere with 4.6 nl of treatment or controls, and allowed to develop as normal. A) Stage 20 Xenopus
embryos after control injections and 400 μM AR28 injections, clearly showing a ‘Y’ neural tube. B) Stage 40 Xenopus embryos after
control injections and AR28 injections, showing duplicated axis with varying degree of severity. C) Chordin In-situ hybridisation in
Xenopus embryos showing clear secondary regions of expression in 400 μM injected embryos. D) AR28 can stimulate TCF/LEF1
transcription factor activation in a dose- and time-dependent manner TOPFlash analysis of C3H10T1/2 cells after 24 h of treatment
with Wnt activators. Values given as the mean fold change ± standard deviation of normalised data from three independent biological
samples, each consisting of six independently transfected and treated replicates.
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tivators of canonical Wnt signalling, LiCl and recombinant
Wnt3a, over a 24 h treatment period (Fig. 1D). LiCl is commonly
used at 20 mM, while recombinant Wnt3a is shown to cause a
range of effects over concentrations of 5–100 ng/ml (Liu et al.,
2009). Using the TOPFlash assays, we demonstrated that AR28
caused a dose-dependent increase in luciferase activity with
2.5 μM AR28 inducing an approximate 1000-fold increase over
controls, comparable to effects caused by Wnt3A (100 ng/ml).
LiCl (20 mM) was less effective at eliciting a Wnt response,
causing a 10-fold increase in reporter activity compared to NaCl
controls.
The TOPFlash reporter was also able to identify changes
in transcriptional activation in response to differing
concentrations and treatment duration of AR28 relative
to the commonly used GSK3β inhibitor, BIO. AR28 admin-
istration generated a strong TCF reporter response in
a time- and concentration-dependent manner, with in-
creasing luciferase activity with concentration and time,(Fig. S3A). However, BIO at similarly high concentrations
generated early increases in reporter expression, inducing
an approximate 100-fold increase in expression at 40 h
(Fig. S3B) compared to over 1000-fold increase by AR28
at the same time point. Furthermore, the Wnt reporter
response was prolonged for several hours after AR28
removal before declining again over time, suggesting a
reversible activation of the canonical Wnt signalling path-
way (Fig. S3C).Wnt stimulation by AR28 inhibits
adipogenic differentiation
The effect of AR28 on the adipogenic differentiation of BMSCs
was analysed by Oil Red O staining and quantified by extraction
and colourimetric measurement (Fig. 2A–B). A large and
significant increase in Oil Red O staining was generated when
BMSCs were treated with adipogenic media, however this
Figure 2 AR28 inhibits adipogenic differentiation of BMSCs. A) Oil Red O staining of day 14 BMSC adipogenic cultures treated with
vehicle control or AR28. B) Absorbance at 490 nm of extracted Oil Red O from day 14 BMSC adipogenic cultures treated with AR28 or
vehicle control. C) DNA content of BMSC cultures (μg DNA) in basal and adipogenic medium at days 7 and 14, in the presence and
absence of AR28. Significance calculated relative to adipogenic DMSO control at respective time points unless otherwise stated.
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as 0.05 μM AR28 and a complete absence of Oil Red O staining
was generatedwith 0.5 μMAR28,without affecting cell number
(Fig. 2C). The remaining lipid droplets in treated samples were
of reduced size as well as number, implying that AR28 inhibited
adipogenesis of BMSCs. In addition to the Oil Red O analysis of
the adipogenic differentiation of BMSCs, a high-content imaging
system was used to study the effect of AR28 on the adipogenic
differentiation of ADSCs (Fig. S4). The ADSCs were subjected to
adipogenic media and a broad range of AR28 concentrations.
Following FABP5, BODIPY and Hoecsht staining, automated
imaging and image analysis was performed (Fig. S4A). In
agreement with the work in BMSCs, this method demonstrated
that 50–60% of ADSCs had double positive staining after14 days, which was significantly (p b 0.05) reduced by
0.063 μM AR28 to approximately 45%, while 0.2 μM AR28
reduced adipogenesis to 15% (Fig. S4B). At low AR28
concentrations, below 0.02 μM, adipogenesis was very slightly
but significantly stimulated by ~2–3% at day 7 (Fig. S4B),
however, these increases were not seen at the later time point.
During adipogenic differentiation of ADSCs, proliferation was
reduced, and this reduction was reversed to some extent with
AR28-induced inhibition of adipogenesis with modest but
significant increases in cell number with 0.063 and 0.2 μM
AR28 treatment in adipogenic conditions (Fig. S4C). Con-
centrations of 0.63 μM and above had a detrimental effect on
cell number, likely caused through toxicity after 2 weeks of
administration.
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on osteogenesis
The effect on activation of canonical Wnt signalling on
osteogenic differentiation of BMSCs was initially investigated
using standard differentiation inducers; β-glycerophosphate,
L-ascorbic acid and dexamethasone. Cells were cultured in this
cocktail for up to three weeks in the presence or absence
of AR28. Early differentiation was detected by alkaline phos-
phatase (ALP) histochemistry and activity assays; ALP levels
decrease in the later stages of osteogenesis. These findings
demonstrated a clear reduction in ALP activity in response to
AR28 in BMSCs. This inhibition can be visualised by ALP enzyme
histochemistry (Fig. 3A) and enzyme activity assays (Fig. 3B),
where AR28 concentrations of 0.1–0.5 μM generated a sig-
nificant reduction in ALP activity in a dose-dependent manner.
Repeat experiments in two other donors showed similar
reductions in ALP activity (Figs. S5A + B, example donor
shown). The analysis of mineralisation by von Kossa staining
also showed a reduction in mineralised nodule formation upon
AR28 administration (Fig. 3A). A second donor presented lower
levels of von Kossa staining in response to osteogenic con-
ditions; however this staining was also reduced by the
administration of AR28 to the culture (Fig. S5B). The use of a
common alternative stain for mineralisation which identifies
calcium rather than phosphate deposition, Alizarin Red S
(AR-S), generated slightly different results, showing no clear
effect of AR28 on staining intensities (Figs. 3C + D), which was
reproducible across donors (Fig. S5C). These data demonstrate
that under standard dexamethasone-induced osteogenic con-
ditions, Wnt activation through AR28 significantly inhibits ALPFigure 3 Effect of AR28 on dexamethasone induced osteogenes
(including dexamethasone) BMSCs at day 21 of differentiation.
independently treated samples of same donor and passage. Significan
Red S staining and D) quantification of AR28 treated osteogenic (incactivity, but has no or mild inhibitory effects of mineralisation
in vitro.
Work by other groups (Eijken et al., 2008; Krause et al.,
2010) has shown that canonical Wnt signalling may enhance
early osteogenic differentiation of BMSCs. To test whether
this was the case in our system, BMSCs were cultured in
media containing β-glycerophosphate and L-ascorbic acid but
excluding dexamethasone and exposed to AR28.When analysed
by ALP enzyme histochemistry under these conditions, small
but significant increases in ALP activity within treated wells
could be detected at AR28 concentrations of 0.05 and 0.1 μM
(Fig. 4A), but reduced again by treatment with 0.5 μM AR28. A
second donor showed increases in ALP enzyme histochemistry
with all concentration of AR28 used, 0.05–0.5 μM (Fig. S6A).
Similarly, small increases in ALP activity could be detected
using the ALP colourimetric enzyme assay by AR28 at 0.05 and
0.1 μM, when studied on a per culture basis (Fig. 4B). However,
these increases were not apparent when normalised on a per
cell basis due to increased cell numbers in AR28-treated
samples (Fig. 4C). Control cultures grown in the osteogenic
media excluding dexamethasone showed undetectable levels of
von Kossa staining (Figs. 4A and S6A), and low levels of AR-S
staining (Fig. 4D and S6B), supporting the notion that these
conditions promote early osteogenic differentiation and not
mineralisation. AR28 had no effect on the levels of von Kossa
staining compared to controls, but increases in mineralisation
of the cultures could be detected by AR-S staining in response to
dose-dependent AR28 treatment (Figs. 4D + E and S6B). These
data suggest that in the absence of dexamethasone, AR28-
mediatedWnt signalling can elevate the osteogenic response in
amanner that is dependent on BMSC number. Interestingly, theis. A) ALP and von Kossa staining of AR28 treated osteogenic
B) ALP activity of BMSCs. n = 6, ± standard deviation of 6
ce relative to DMSO control at respective time points. C) Alizarin
luding dexamethasone) BMSCs at day 21 of differentiation.
Figure 4 Effect of AR28 on dexamethasone independent osteogenesis. A) ALP and von Kossa staining of AR28 treated osteogenic
(excluding dexamethasone) BMSCs at day 21 of differentiation. B,C) ALP activity of BMSCs. B) Overall ALP activity in the well. C) ALP
activity relative to DNA. n = 6, ± standard deviation of 6 independently treated samples of same donor and passage. Significance
relative to DMSO control at respective time points. D) Alizarin Red S staining of AR28 treated osteogenic (excluding dexamethasone)
BMSCs at day 21 of differentiation. C) Quantification of Alizarin Red S staining at days 7, 14 and 21 of differentiation. Data shown all
from the same donor, reproducible between experiments.
422 D.A. Cook et al.highest AR28 treatment, 0.5 μM, generated the strongest
mineralisation, but did not cause the increases in ALP staining
generated at the lower AR28 concentrations (Figs. 4A + D).
We demonstrated by DNA analysis (Fig. 5A) and MTT
(Fig. S7A) assays that exposure of BMSCs to AR28 increased
cell number. The greatest increases relative to controls were
observed in differentiation media excluding dexamethasone,
with maximum increases in DNA content at day 14 (Fig. 5A).
Therefore we proposed that the increases in differentiation/
mineralisation induced by AR28 in the absence of dexametha-
sone were dependent on elevated cell numbers. To test this
hypothesis, BMSCs were treated with mitomycin C to inhibit
their proliferation (Fig. 5B insert), and subjected to osteogenic
medium excluding dexamethasone, with and without AR28
addition. As in previous studies, AR28 caused increases in AR-S
staining by 7 days, however when proliferation was inhibited
this increase in mineralisation was blocked (Figs. 5B + C).
However the increased mineralisation detected was not solely
due to an increase in total cell number as simply doubling
the initial seeding density had no effect on AR-S staining
(Figs. 5B + C).
To determine if Wnt signalling could prime BMSCs for
osteogenesis, confluent BMSC cultures where pretreated for
7 days with AR28 in basal medium. AR28 was subsequently
removed and differentiation media was placed on the cells
for up to 14 to 21 days. When cultured in osteogenic media
excluding dexamethasone, increases in ALP enzyme histo-
chemistry were detected in AR28 pre-treated samples relative
to the DMSO control (Fig. 6A). However no von Kossa staining
was present, similar to observations described above duringcontinuous AR28 treatment when dexamethasone was ex-
cluded. Statistically significant increases in ALP activity could
be detected using the enzyme activity assay (Fig. 6B) in
cultures pre-treated with AR28 prior to the addition of
osteogenic media excluding dexamethasone. However, when
complete dexamethasone-including osteogenic medium was
used, increases in both ALP enzyme histochemistry and von
Kossa staining could be detected in AR28 pretreated samples
(Fig. 6A). In contrast, when BMSCs were cultured in adipogenic
media no clear changes in adipogenesis could be detected
after pre-treatment with AR28 relative to the DMSO control
samples (Fig. S7B).AR28 enhances BMP2 induced osteogenesis
BMP signalling has been shown to stimulate osteogenic
differentiation of BMSCs. Here we have shown that 100 ng/ml
BMP2 added to standard growth media, stimulated small, but
significant, increases in the early osteogenic marker, ALP, in
BMSC cultures (Figs. 7A[left panels] and B). Furthermore, AR28
alone did not generate significant increases in ALPwithin 7 days
(Figs. 7A[top panels] and B). However, when AR28, most
notably at 0.5 μM, was added together with 100 ng/ml BMP2,
large increases in ALP activity were detected, implying en-
hanced osteogenesis (Figs. 7A[lower panels] and B). However,
the synergistic enhancement of osteogenesis created by BMP2
and AR28 was not accompanied by large increases in cell
number (Fig. 7B), suggesting that increases in cell proliferation
are not responsible for this increase in ALP activity. Real-time
Figure 5 AR28 increases cell numbers in osteogenic cultures. A) AR28 increases cell numbers in osteogenic cultures. Graph of DNA
content of BMSC cultures (μg DNA) in basal and osteogenic (including (+Dex) and excluding (-Dex) dexamethasone) medium, in the
presence and absence of AR28. Samples taken at days 4, 7 and 14. Mean ± standard deviation of 6 independently treated technical
replicates. Significance relative to DMSO control at respective time points. B) Alizarin Red S staining and C) quantification of day 7
osteogenic BMSC cultures treated with AR28. Cells were seeded at density indicated and treated with mitomycin C for 2 h prior to
initiation of differentiation. Graph on lower right panel of B) shows MTT analysis of cell number at day 0 and 7 of control and
mitomycin C treated BMSCs seeded at 2 × 104 cells/cm2, demonstrating the inhibition of proliferation by mitomycin C.
423Wnt-dependent osteogenic commitment of BMSCs using a novel GSK3β inhibitorPCR was also used to study the effect of AR28 on BMP2-induced
differentiation of BMSCs from three separate donors, with a
single donor presented in Fig. 7C (ΔCT values ± standard
deviation for all three donors are presented in Table S2).
Donor variation prevented the statistical analysis of the three
combined donors and restricted the analysis to comparison of
trends, however clear patterns could be identified within all
three donors. BMP2 alone generated small increases in ALP
expression levels, and AR28 was able to synergistically enhance
this expression. BMP2 treatment caused a slight increase in
Runx2 expression across all donors, but this was not affected
by AR28 treatment. As BMPs are also known to enhancechondrogenesis (Banerjee et al., 2001; De Luca et al., 2001),
the expression of Sox9, Coll2A1 and Aggrecan were measured.
The expression of these genes were clearly increased by the
addition of BMP2 to themedia across all three donors to varying
degrees, but reduced again with the inclusion of 0.5 μM AR28
(Fig. 7C).Discussion
Studies into canonical Wnt signalling in BMSCs and particularly
during osteogenesis, often generate apparently conflicting
Figure 6 Pre-treatment with AR28 enhances osteogenesis.
BMSCs were treated for one week in basal medium and AR28
at concentrations shown. The medium was then exchanged for
osteogenic medium (including or excluding dexamethasone),
without AR28, and cultured for a further 7 or 14 days. A)
Brightfield images of ALP enzyme histochemistry (pink) and
von Kossa staining (brown/black) after a total of 21 days
culture. B) ALP enzyme activity assay 0, 7 and 14 days after
osteogenic medium (excluding dexamethasone) was added to
the cells. n = 6, ±standard deviation of 6 independently
treated samples of same donor and passage.
424 D.A. Cook et al.data. One explanation for this is likely due to the varying use of
Wntmimetics. We have demonstrated that a specific GSK3α/β
inhibitor (Gambardella et al., 2011), AR28, is a potent ac-
tivator of canonical Wnt signalling in a mouse cell line,
C3H10T1/2 and human BMSCs. The extent of Wnt activation
was dependent on both AR28 concentration and length of
treatment. Furthermore, Wnt activation was reversible with
the removal of AR28 leading to declining Wnt signalling over
time. The responses generated were of comparable amplitude
to that of other common canonical Wnt activators when used
at concentrations of 0.1 to 2.5 μM. AR28 also induced a
functional Wnt response in vivo, generating classic canonical
Wnt-mediated duplication of embryonic axes in X. laevis
embryos. AR28 can therefore be used as a novel and specific
method for regulated induction of canonical Wnt signalling in
mesenchymal progenitors.Here, AR28 induced a clear dose-dependent inhibition of
BMSC adipogenic differentiation over a two week period.
This confirmed the inhibitory effect of canonical Wnt
stimulation on adipogenesis reported previously (Prestwich
& Macdougald, 2007), whilst at the same time demonstrating
the sensitivity of AR28 as a pharmacological manipulator of
the canonical Wnt pathway. The ability to easily manipulate
the degree of canonical Wnt signalling within cells has
allowed us to use AR28 as a powerful tool for unlocking the
poorly understood effects of canonical Wnt signalling on the
osteogenic differentiation of BMSCs. Firstly we have shown
that activation of the canonical Wnt signalling pathway
inhibits the osteogenesis of BMSCs when differentiated using
the standard induction cocktail of β-glycerophosphate,
L-ascorbic acid and dexamethasone. This is in agreement
with other work (Boland et al., 2004; Liu et al., 2009;
de Boer et al., 2004a) demonstrating a reduction in ALP and
mineralisation in response to canonical Wnt signalling in
standard osteogenic medium. However, in osteogenic media,
excluding dexamethasone, enhancement of early osteogenesis
and formation of precursor cells was detected. This has been
noted in recent papers which have proposed the enhancement
of the early differentiation process, accelerating the cells
though the osteoblast precursor stage in response to Wnt
signalling (Eijken et al., 2008; Krause et al., 2010. Krause et al.
(2010)) found that activation of Wnt signalling using BIO
increased AR-S staining during dexamethasone-dependent
osteogenesis, whereas AR28 had little effect on biomineral-
isation under these conditions. These discrepancies may relate
to the different mechanisms of action of BIO versus AR28. BIO
also acts via JAK/STAT signalling pathway, inducing apoptosis
(Liu et al., 2011) and may inhibit mitosis (Damiens et al.,
2001), which we find essential to Wnt-mediated effects on
osteogenesis. In line with this, we have shown that AR28
caused an increase in the number of cells with elevated ALP
expression. In contrast to previous work, we also showed that
in our system, dexamethasone- independent osteogenic
stimulation in the presence of elevated Wnt signalling could
generate small but clear increases in mineralisation, which
were dependent on continued proliferation. These changes
were more readily detectable using AR-S staining than von
Kossa, suggesting another reason for the potential discrep-
ancies in the literature. We propose that AR28 and therefore
canonical Wnt signalling is acting to stimulate the proliferation
of the cells, most likely the osteogenic precursor cells within
the population, to enhance the osteoprogenitor pool, allowing
for elevated mineralisation. This is supported by our observa-
tion that one week pre-treatment of the heterogeneous BMSC
population with AR28 enhanced osteogenesis, but did not
affect adipogenesis, indicating lineage-specificity. These find-
ings share similarities with those of Gambardella et al. (2011)
who identified in vivo amplification of mesenchymal pro-
genitors upon AR28 administration. This amplification was
reflected as an enhancement of ex vivo CFU-O, but not CFU-A
formation, implying a preference of these amplified precursors
for osteogenesis. However, more detailed work studying the
proliferation of cells within the BMSC population is required to
confirm this hypothesis and fully understand the role of
canonical Wnt signalling in BMSC lineage commitment. Our
work and that of others (Eijken et al., 2008; Krause et al.,
2010; Quarto et al.) emphasises the role of target cell type
and stage of differentiation in the effect of canonical Wnt
Figure 7 AR28 enhances BMP2-induced osteogenesis of BMSCs. A) Brightfield image of ALP/von Kossa stained BMSCs treated with
combinations of BMP2 (100 ng/ml) and AR28 for 7 days. B) ALP activity (nmoles pnp/min/ugDNA) of BMSC cultures treated with
combinations of BMP2 (100 ng/ml) and AR28 for 7 days, alongside the μg DNA per culture as an indication of cell number. Significance
relative to DMSO control for same media, unless otherwise stated. n = 6, ±standard deviation of 6 independently treated samples of
same donor and passage. C) Representative donor for qPCR analysis of chondrogenic and osteogenic genes during treatment with a
combination of BMP2 and AR28 in basal medium of BMSCs (Donor A in Table S2). Gene expression was normalised to RPS27A, and
plotted as fold change relative to 24 hour basal medium control. ΔCT ± standard deviation values for all donors are given in Table S2.
425Wnt-dependent osteogenic commitment of BMSCs using a novel GSK3β inhibitorsignalling on mesenchymal differentiation, and provides an
explanation for discrepancies in the published literature
on the effect of canonical Wnt signalling on osteogenesis.
Furthermore, as BMSCs are primary cells, there are often
differences in response from different donors, a property that
was identified in thework presented here, likely due in part, to
the heterogeneous starting populations (Minguell et al., 2001),
could also lead to some of the varied observations in the
literature. These findings also demonstrate that Wnt signalling
can enhance osteogenesis through BMP-dependent and inde-
pendent mechanisms; in the absence of BMP, this is achieved
by increasing osteoprogenitor cell number, whereas in the
presence of BMP, Wnt signalling appears to cooperatively
stimulate the differentiation process without affecting pro-
liferative activity. The requirement for functional canonical
Wnt signalling in BMP-induced osteogenesis has been notedbefore in mouse stromal cell lines (Rawadi et al., 2003) and
mouse models (Chen et al., 2007), and furthermore has been
shown to have a synergistic effect in C3H10T1/2 cells (Tang et
al., 2009). However, whilst C3H10T1/2 cells are commonly
used as a model for stromal cell differentiation, they behave
differently to BMSCs in that they will only form osteoblasts in
the presence of high levels of BMPs, placing speculation on the
accuracy of them as a model system. The work presented here
demonstrates a similar synergetic effect of BMP and canonical
Wnt signalling, but in the more robust model of human BMSCs.
In addition to this synergistic effect of BMP2 and AR28 on
osteogenesis, we demonstrated an inhibitory effect of AR28
on BMP2-induced expression of chondrogenic genes. Canonical
Wnt signalling has been shown to be important in the
commitment of progenitor cells to form either chondrocytes
or osteoblasts during development by a selection of conditional
426 D.A. Cook et al.β-catenin knockouts and Wnt14 over-expression studies in
mousemodels (Day et al., 2005; Hill et al., 2005). These studies
demonstrated that increased canonical Wnt signalling within
the progenitor cells promoted osteogenesis and chondrocyte
hypertrophy and blocked chondrocyte differentiation, while
canonical Wnt inhibition resulted in increased cartilage
formation at the expense of osteogenesis. The results described
here also suggest that the interplay between these two key
signalling pathways is important in this bi-lineage commitment
decision of human BMSCs, in which canonical Wnt signalling can
act as a switch to alter the differentiation fate from a chon-
drocyte to an osteoblast, a process that is necessary for
endochondral bone formation. Further work is required, study-
ing later markers of both osteogenesis and chondrogenesis to
determine whether these signals alone are capable of fully
differentiating BMSCs towards these two lineages, or whether
further stimulation is required to generate fully matured cells.
The work presented here also offers an explanation for
some of the discrepancies between findings in humans and
mice. Osteogenesis of mouse cells rarely uses dexametha-
sone to induce differentiation, and demonstrate increased
expression of bone markers upon canonical Wnt stimulation
(Kulkarni et al., 2006; Bennett et al., 2005; Jackson et al.,
2005), while the majority of human BMSC osteogenic differ-
entiation requires the use of dexamethasone to stimulate
differentiation and mineralisation, which is inhibited by
canonical Wnt signalling (Boland et al., 2004; De Boer et al.,
2004b). Yet, if human BMSCs are differentiated without
dexamethasone we and others (Krause et al., 2010) have
shown small increases in early stage differentiation can be
detected in response to canonical Wnt signalling, suggesting
the differences may be due to the difference in differ-
entiation stimulation and not species.
Work by Wang et al. (2009) identified the ability of a
canonical Wnt signalling to rescue GC-induced osteoporosis
while here we identify the possible mechanisms behind this
effect. Our results indicate the importance of Wnt-induced
proliferation in the early stages of osteogenic differentiation
and that canonical Wnt signalling inhibits dexamethasone-
induced differentiation and maturation of BMSCs. Therefore,
manipulation of canonical Wnt signalling has the potential to
reduce GC-induced osteoporosis by preventing final matura-
tion and apoptosis of osteoblasts, increasing the number of
osteoblast precursors through elevated proliferation and
blocking adipogenic differentiation, limiting depletion of the
osteogenic progenitor pool and allowing for the maintenance of
bone density. Therefore, controlled enhancement of canonical
Wnt signalling using chemical modifiers such as AR28, offers
great therapeutic potential for the treatment of bone disorders.
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